Plain-English translation of NCT06933277 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →This is a real-world study tracking how selinexor works when combined with two other medications (bortezomib and dexamethasone) to treat multiple myeloma. Researchers are collecting safety and effectiveness information from patients already receiving this medication combination in Italian hospitals and clinics. The goal is to understand how well this treatment works and what side effects patients experience outside of a controlled research setting.
While the medication combination has been approved for use in Italy, doctors want to learn more about how it performs in everyday practice and whether it works as well as expected in different patient situations.
You likely qualify if…
You likely don't qualify if…
You would not receive any new treatment—you would simply be monitored as you continue receiving the medication combination you are already taking. The research team would collect information from your medical records about how the treatment is working and any side effects you experience. The study will follow patients for approximately 36 months, with at least 12 months of observation to track your response to treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy
Enrollment target
~159 participants
Started
August 2025
Primary completion
August 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Paola Fazi
UOC di Ematologia Policlinico S.Orsola AOU di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.